According to Korea Food and Drug Administration (KFDA), Supect, a drug manufactured by Ilyang Pharmaceutical has been approved to treat leukemia in those resistant to currently available anti-leukemia treatment Gleevec drug, xinhuanet.com reported citing Yonhap News Agency.
The increased demand for the new treatment has been observed due to the rise in the number of patients becoming resistant to Gleevec.
Clinical data demonstrated that Supect is safer than Gleevec and causes no side effects such as cardiotoxicity and pulmonary edema, xinhuanet.com added, citing Yonhap.